[A21-161] Cemiplimab (basal cell carcinoma) - Addendum to Commission A21-97
Last updated 20.01.2022
Project no.:
A21-161
Commission:
Commission awarded on 07.12.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adult patients with locally advanced or metastatic basal cell carcinoma who were previously treated with a hedgehog signal pathway inhibitor and show disease progression or intolerance to it during this treatment
Unchanged after addendum:
Added benefit not proven.
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A21-97 | Cemiplimab (basal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2022-01-20 A G-BA decision was published.